DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

Inclusion Criteria: * Subjects who are competent to provide written consent * Aged 35 to 80 years * Subjects with diabetes and/or chronic kidney disease must have a mean systolic blood pressure ≥130 mmHg * All other subjects must have a mean systolic blood pressure ≥140 mmHg * Receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic * Female subjects of non-childbearing potential (i.e., post-menopausal for at lest 2 years; surgically sterile) Exclusion Criteria: * Average sitting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg * Serum ALT or AST \>2 x the upper limit of the normal range (ULN) * Subjects who have experienced myocardial infarction, unstable angina pectoris, or a cerebrovascular accident (CVA) within 6 month; or sick sinus syndrome or second or third degree atrioventricular block, atrial fibrillation or recurrent atrial tachyarrhythmia, recurrent ventricular tachycardia, or symptomatic bradycardia * Implanted pacemakers or implanted cardioverter defibrillator (ICD) * Symptomatic congestive heart failure requiring treatment * Hemodynamically significant valvular heart disease * Type I diabetes mellitus * Hemodialysis or peritoneal dialysis; or history of renal transplant * Diagnosis or recurrence of malignancy within the past 3 years * Sleep apnea, unless a recent sleep study demonstrates arterial oxygen saturation greater than or equal to 90% * Subjects who perform alternating shift or night work * Subjects who have participated in a clinical study involving another investigational drug or device within 4 weeks prior to Screening